Patients win Patent War
It's double trouble for global pharma companies in India. On April 1, a Supreme Court bench comprising Judges Aftab Alam and Ranjana Desai dismissed Swiss drug major Novartis AG's seven-year-old plea seeking
Bayer Pharmaceuticals
-
Pharma majors named in clinical trial death list
Companies say they follow global standards in India as well Drug majors such as Novartis, Pfizer, Bayer Healthcare, Bristol Mayer Squibb, Sun Pharmaceutical and Dr Reddy’s Laboratories were allegedly involved in clinical trials in which 438 persons died in 2011, according to confidential government data reviewed by Business Standard. While the companies argue they follow the global standards, experts point at the absence of sound regulations as the main culprit. Although the number of deaths in clinical trials has been growing through the years, it fell in 2011 from the previous year mainly because of flat growth in the clinical research market in India.
-
Bayer challenges India compulsory license ruling
German pharmaceutical company Bayer AG has formally lodged a challenge against a landmark Indian ruling that allowed a domestic generic drug-maker to produce a low-cost version of an anti-cancer drug for
-
The compulsory licence for Nexavar - A landmark order
The compulsory licence issued to Natco for manufacture of the anti-cancer drug Nexavar is a landmark decision on many grounds – the first one in India since the 2005 amendment to the 1970 Patents Act and
-
A strike against pharma MNCs
The compulsory licence for Nexavar is only the beginning of a new battle over drug prices. (Editorial)
-
We will intervene to make critical drugs affordable, says govt
The government today asserted India would invoke the flexibility it had under the WTO agreement on Trade Related Intellectual Property Rights (TRIPs) for compulsory licensing of patented drugs to ensure
-
India grants first compulsory license to generic drug producer
In a landmark move, the Indian Patent Office announced on Monday that it has issued its first compulsory license to a domestic generic drug-maker. The decision effectively ends German pharmaceutical company
-
Govt uses special powers to slash cancer drug price
Mumbai: In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat
-
Bayer files patent case against Cipla
GERMAN drugmaker Bayer has filed a patent infringement case against Cipla, the largest domestic drugseller, to stop the Mumbaibased company from selling its generic version of Bayer
-
Cipla can sell copy of Bayers cancer drug
Delhi HC Ruling Big Victory For Indian Drugmakers IN A major win for Indian pharma companies, the Delhi High Court (HC) on Tuesday dismissed German drug major Bayer Healthcare